MDMB-5Br-INACA
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H18BrN3O3 |
Molar mass | 368.231 g·mol−1 |
3D model (JSmol) | |
| |
|
MDMB-5Br-INACA is an indazole-3-carboxamide derivative which has been sold as a designer drug.[2] Surprisingly it appears to produce psychoactive activity despite the lack of a "tail" group at the indazole 1-position, but is of relatively low potency and has been encountered being misrepresented as other illicit drugs such as MDMA.[3][4]
Use as a precursor
MDMB-5Br-INACA is believed to be used as a precursor in the synthesis of synthetic cannabinoids. It has been sold online as "half finished" synthetic cannabinoids, sometimes as a "chemistry kit" with other compounds required to complete the reaction. This reaction would complete MDMB-5Br-INACA by giving it a "tail" group required for high cannabinoid activity. Other precursors lacking a tail chain have also been marketed such as (ADB-5-Br-INACA),[5] (CH-IATA), (ADB-IACA), and (ADB-5’Br-EZO-CA). This may be due to increasing legality changes worldwide on synthetic cannabinoids.[6][7]
Legality
In the United States, MDMB-5Br-INACA is unscheduled at the federal level as of May 22nd, 2023.
North Dakota has placed MDMB-5Br-INACA (along with ADB-5'Br-BINACA, ADB-5'Br-BUTINACA and ADB-5-Br-INACA) into Schedule I on 04/27/2023.[8]
See also
References
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- ^ "CFSRE Analysis Report" (PDF). Indianapolis-Marion County Forensic Services Agency. 17 May 2022.
- ^ "Drug testers warn of new synthetic cannabinoid being sold as MDMA". New Zealand Herald. 5 August 2022.
- ^ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, et al. (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID 37903509. S2CID 264671035.
- ^ Choi H, Kim S, Jang H, Kim HJ, Choe S (September 2022). "Identification of a novel bromoindazole synthetic cannabinoid analogue in seized e-cigarette liquid: ADB-BRINACA". Forensic Science International. 338: 111385. doi:10.1016/j.forsciint.2022.111385. PMID 35863161.
- ^ "Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms" (PDF). Advisory Council on the Misuse of Drugs. 2022.
- ^ Andrews R, Jorge R, Christie R, Gallegos A (April 2023). "From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day". Drug Testing and Analysis. 15 (4): 378–387. doi:10.1002/dta.3422. PMID 36507715.
- ^ "AN ACT to amend and reenact sections 19-03.1-05, 19-03.1-11, and 19-03.1-13 of the North Dakota Century Code, relating to the scheduling of controlled substances; and to declare an emergency" (PDF). Sixty-eighth Legislative Assembly of North Dakota in Regular Session. 3 January 2023.